Seres Therapeutics Inc logo

MCRB

Seres Therapeutics Inc

$5.69

Earnings Summary

Revenue
$9.06Mn
Net Profits
$-21.95Mn
Net Profit Margins
-242.4%

Highlights

Revenue:

Seres Therapeutics Inc’s revenue fell -60.66% since last year same period to $9.06Mn in the Q3 2018. On a quarterly growth basis, Seres Therapeutics Inc has generated 96.34% jump in its revenue since last 3-months.

Net Profits:

Seres Therapeutics Inc’s net profit fell -216.5% since last year same period to $-21.95Mn in the Q3 2018. On a quarterly growth basis, Seres Therapeutics Inc has generated 21.01% jump in its net profits since last 3-months.

Net Profit Margins:

Seres Therapeutics Inc’s net profit margin fell -704.43% since last year same period to -242.4% in the Q3 2018. On a quarterly growth basis, Seres Therapeutics Inc has generated 59.77% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Seres Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.45
EPS Estimate Current Year
-0.45

Highlights

EPS Estimate Current Quarter:

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 4.26% jump from last quarter’s estimates.

EPS Estimate Current Year:

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.45.

Key Ratios

Key ratios of the Seres Therapeutics Inc post its Q4 2022 earnings

Return on Assets (ROA)
-0.44
Return on Equity (ROE)
-3.52

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Seres Therapeutics Inc’s return on assets (ROA) stands at -0.44.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Seres Therapeutics Inc’s return on equity (ROE) stands at -3.52.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2020-07-28
-0.26
-0.28
-7.69%
2020-11-09
-0.25
-0.36
-44%
2020-05-07
-0.28
-0.28
0%
2021-03-02
-0.28
-0.23
17.86%

Company Information

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.

Organisation
Seres Therapeutics Inc
Headquarters
200 Sidney Street, Cambridge, MA, United States, 02139
Employees
431
Industry
Health Technology
CEO
Eric Shaff